FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906179924> ?p ?o ?g. }

• W2906179924 abstract "Background Despite of the good clinical efficacy of denosumab for primary osteoporosis, 2017 American College of Rheumatology guideline for treatment of glucocorticoid-induced osteoporosis (GIOP) placed denosumab as second-line treatment because of lack of clinical experiences with concomitantly use of immunosuppressive agents. Moreover, recently large phase 3 study in primary osteoporosis revealed that transition from teriparatide to denosumab continuously increased bone mineral density (BMD)1 However, there is still remain unclear whether prior treatment affect to the efficacy of denosumab in GIOP. Objectives The aim of this study is to compare the therapeutic effect of denosumab in GIOP between previous anti-osteoporotic treatments, and to investigate the factor that influence the efficacy of denosumab in GIOP. Methods Sixty-six patients for whom treated by denosumab, were enrolled. All patients were receiving several dosages of predonisolone (PSL) (2–20 mg) for RA and connective tissue diseases at initiation of denosumab. 23 patients had been treated with daily teriparatide and 27 patients had been treated with bisphosphonate (BPs) prior to denosumab. The rest 16 patients had not been treated by anti-osteoporosis medication at initiation of denosumab. We evaluated BMD at lumbar spine and bone turnover markes (NTX, BAP and P1NP) every 6 months for 12 months. The changes in BMD was compared among these 3 groups at 6 months and at 12 months. To assess the factors which influences clinical response of denosumab in GIOP, univariate and multivariable ordinal logistic regression analyses were used. Results Mean percentage change in BMD of lumbar spine from baseline to 6 and 12 months were significant (2.85% increased; p Conclusions Our present study demonstrated that denosumab increased BMD in GIOP regardless of prior anti-osteoporotic treatment in ‘real-world’ settings. We should consider denosmab treatment for GIOP, especially who are treated by much dose of glucocorticoids or at the time when the efficacy of BPs is diminished. Reference [1] Leder BZ, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet2015;386(9999):1147–55. Disclosure of Interest None declared" @default.
• W2906179924 created "2019-01-01" @default.
• W2906179924 creator A5000556430 @default.
• W2906179924 creator A5018912172 @default.
• W2906179924 creator A5022076444 @default.
• W2906179924 creator A5036443534 @default.
• W2906179924 creator A5070326257 @default.
• W2906179924 creator A5074758212 @default.
• W2906179924 date "2018-06-01" @default.
• W2906179924 modified "2023-09-28" @default.
• W2906179924 title "THU0494 The efficacy of denosumab in glucocorticoid-induced osteoporosis did not depend on prior treatment but was affected by the dosage of glucocorticoid" @default.
• W2906179924 doi "https://doi.org/10.1136/annrheumdis-2018-eular.6430" @default.
• W2906179924 hasPublicationYear "2018" @default.
• W2906179924 type Work @default.
• W2906179924 sameAs 2906179924 @default.
• W2906179924 citedByCount "0" @default.
• W2906179924 crossrefType "proceedings-article" @default.
• W2906179924 hasAuthorship W2906179924A5000556430 @default.
• W2906179924 hasAuthorship W2906179924A5018912172 @default.
• W2906179924 hasAuthorship W2906179924A5022076444 @default.
• W2906179924 hasAuthorship W2906179924A5036443534 @default.
• W2906179924 hasAuthorship W2906179924A5070326257 @default.
• W2906179924 hasAuthorship W2906179924A5074758212 @default.
• W2906179924 hasBestOaLocation W29061799241 @default.
• W2906179924 hasConcept C126322002 @default.
• W2906179924 hasConcept C198451711 @default.
• W2906179924 hasConcept C2776286101 @default.
• W2906179924 hasConcept C2776541429 @default.
• W2906179924 hasConcept C2776886416 @default.
• W2906179924 hasConcept C2777308945 @default.
• W2906179924 hasConcept C71924100 @default.
• W2906179924 hasConceptScore W2906179924C126322002 @default.
• W2906179924 hasConceptScore W2906179924C198451711 @default.
• W2906179924 hasConceptScore W2906179924C2776286101 @default.
• W2906179924 hasConceptScore W2906179924C2776541429 @default.
• W2906179924 hasConceptScore W2906179924C2776886416 @default.
• W2906179924 hasConceptScore W2906179924C2777308945 @default.
• W2906179924 hasConceptScore W2906179924C71924100 @default.
• W2906179924 hasLocation W29061799241 @default.
• W2906179924 hasOpenAccess W2906179924 @default.
• W2906179924 hasPrimaryLocation W29061799241 @default.
• W2906179924 hasRelatedWork W1911703092 @default.
• W2906179924 hasRelatedWork W2030998618 @default.
• W2906179924 hasRelatedWork W2042561248 @default.
• W2906179924 hasRelatedWork W2064677866 @default.
• W2906179924 hasRelatedWork W2096836622 @default.
• W2906179924 hasRelatedWork W2100415227 @default.
• W2906179924 hasRelatedWork W2127348476 @default.
• W2906179924 hasRelatedWork W2523651260 @default.
• W2906179924 hasRelatedWork W2606358690 @default.
• W2906179924 hasRelatedWork W2790972851 @default.
• W2906179924 hasRelatedWork W2890782207 @default.
• W2906179924 hasRelatedWork W2958108725 @default.
• W2906179924 hasRelatedWork W2968359990 @default.
• W2906179924 hasRelatedWork W3011113572 @default.
• W2906179924 hasRelatedWork W3034033500 @default.
• W2906179924 hasRelatedWork W3040203104 @default.
• W2906179924 hasRelatedWork W3116358764 @default.
• W2906179924 hasRelatedWork W3123605326 @default.
• W2906179924 hasRelatedWork W3129780847 @default.
• W2906179924 hasRelatedWork W3202087077 @default.
• W2906179924 isParatext "false" @default.
• W2906179924 isRetracted "false" @default.
• W2906179924 magId "2906179924" @default.
• W2906179924 workType "article" @default.